Asuragen, a provider of diagnostic products, has unveiled a new molecular technology - Xpansion Interpreter - to map Fragile X Gene.
Subscribe to our email newsletter
Xpansion Interpreter is used to determine the number and location of AGG interruptions associated with expansion of the Fragile X gene and also helps in better understanding of an individual’s risk of having a child with Fragile X syndrome.
Asuragen CEO Matt Winkler said with the ability to clinically determine the number and location of AGG interruptions, the long-time problem of determining the stability of certain Fragile X alleles becomes more clear, creating opportunities to improve patient care.